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Abstract
Background: Among student populations, literature has identified associations between 
prescription opioid misuse and symptoms of depression such as hopelessness, sadness, 
and emotional pain. Thus far, existing literature has yet to investigate associations between 
prescription opioid misuse and depression using validated screening instruments for depression 
when exploring such associations. The purpose of this study was to utilize a validated screening 
tool to explore quantifiable presence of depression among college students who engage in 
recreational prescription opioid misuse (RPOM). Additionally, gender differences in depression 
and co-occurring substance use are examined. 
Methods: Students (n = 104) of a large university in the Southeastern United States who reported 
RPOM within the past 6 months completed instrumentation assessing demographics, substance 
use, as well as, screening tools for depression and possible opioid use disorder (OUD). 
Results: Positive depression screens were significantly higher among females, however, nearly 
56% of participants screened positive for major depression. Though high levels of co-occurring 
substance use were observed among the entire sample, males were significantly more likely to 
report cocaine use, more frequent use of alcohol and marijuana, as well as, exhibit a positive 
screen for disordered opioid use, at a rate 5 times that of their female counterparts. 
Conclusion: Students who engage in RPOM are a particularly heightened-risk subsample of 
the college population who exhibit high levels of depressive symptomatology and substance 
use behavior. Targeted programming and further investigations are needed among this specific 
population. Future studies are encouraged to utilize validated instruments when assessing 
depression among students. 
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Nationally representative data from the United States 
suggests that significantly higher percentages of 
individuals 18-25 years misuse prescription medications 
compared to younger or older age groups.1 In 2015, nearly 
1 million individuals received treatment for prescription 
opioids, 167 000 being 18-25 years.1 Prevalence rates for 
lifetime misuse of prescription opioids among college 
samples vary greatly by study,2,3 with estimates as high as 
32%.4 More proximal recall periods produce estimates, 
typically, much lower at less than 10%.5,6 Pressure from 
the academic environment, perceived peer approval 
and behavior, also the large and diverse social networks 
of college students may contribute to opioid misuse.1,7-10 
Although students have reported misusing opioids for the 
treatment of emotional pain, it appears that motivation for 
misuse is largely recreational.2,6,11 
Characteristics specific to college students place them 
not only at risk for substance use but also to mental 
health complications, particularly depressive symptoms.12 
Many students are experiencing their first glimpse of 
independence, which comes with the loss of their family 
unit, proximal support system, and may lead to risky 
decision making.13 Additionally, school related stress 
has been shown to associate with depression among this 
population.14 The patient health questionnaire 9 (PHQ-9) 
is a common screening tool for major depressive disorder 
(MDD) which has been validated against physician 
diagnosis and is used in research and clinical settings.15,16 
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students recruited from universities across the United 
States, 9% exhibited positive screens for MDD utilizing 
the PHQ-9 instrument.12 Review findings from studies 
incorporating a multitude of depression scales provide 
high prevalence estimates of depression of any form 
among college students, weighted mean rate of 30.6%, 
and further suggest that rates among this population may 
be higher than those among the general population.17 
Further, substance use has also been shown to deteriorate 
the psychological health of students.12,13 Particularly, 
prescription opioid misuse has been linked to suicidality1,18  
and has been associated with the initiation of depression,19 
making recreational opioid misuse a concerning form of 
substance use behavior among students.  
Recent attention given to the current opioid crisis has 
spawned literature indicating a relationship between 
opioid misuse and the existence of depressive symptoms 
and other affective dysregulation among college 
students.6,20,21 Currently, these studies have assessed 
only particular depressive symptomatology, such as, 
hopelessness, sadness, emotional pain, and suicidal 
ideation. As the literature, thus far, has excluded use 
of validated depression screening instruments, it is yet 
unknown to what extent depression may actually exists 
among students who misuse prescription opioids.  
Therefore, the current study was exploratory and held 
three aims. First, to fill a gap in the literature by assessing a 
presence of depression among college students who engage 
in recreational prescription opioid misuse (RPOM) while 
utilizing a validated screening tool for MDD. Gender-
based differences have been presented in the general 
literature regarding the existence of depression17,22,23 and 
misuse of abusable prescription drugs.24 Thus, a second 
study aim was to examine such gender-based differences 
in depression and substance use among this sample 
of opioid misusers. Third, to explore the presence of 
disordered opioid use among this sample, as opioid use 
disorder (OUD) may exacerbate existing mental health 
problems.25
Materials and Methods
Participants and procedures 
Data for the current study were collected in the fall of 2017 
and in conjunction with a larger study investigating the 
belief system underlying RPOM.26 Ethical approval for 
all procedures was obtained from the institution’s ethics 
committee prior to participant contact. Participants were 
students of a large public university located within the 
Southern United States. Individuals reporting past six 
month RPOM were identified from the larger sample 
and asked additional questions specific to the aims of this 
study (i.e. depression and use substance items). These 
individuals (n = 104) reporting past 6-month RPOM 
comprised the current study sample. For recruitment, the 
University’s institutional research office provided 5000 
random email addresses with equal representation by 
gender and academic classification. Recruitment emails 
provided informed consent and an invitation to participate. 
Students were informed that by completing the survey 
they would be eligible to enter a drawing for one of several 
gift cards. Those agreeing to participate opened a link 
taking them to the electronic survey where they provided 
responses to questionnaire items. Response rate from the 
initial 5000 recruitment emails was approximately 20%. 
Following removal of those with large amounts of missing 
data, roughly 10% (104) of the successfully recruited 
students reported past 6-month RPOM, thus meeting the 
inclusionary criteria for the current study. 
Prior to answering specific questions, participants were 
introduced to an operational definition of “recreational 
misuse” (i.e. to get high, for euphoric effects, to have 
fun, relax, or experiment). Students were also provided 
examples of drugs qualifying as opioid pain relievers (i.e. 
opioids like Vicodin, OxyContin, Tylenol 3, Percocet, 
Darvocet, buprenorphine, morphine, hydrocodone, 
oxycodone, methadone, fentanyl, or other such opioids). 
Questionnaire items assessed factors such as demographics, 
misuse of opioid medications and other substances, as 
well as, screener instruments for depression and possible 
OUD. Upon completion of the survey, participants were 
presented with a link to the University’s counseling 
support center where they could find information about 
available resources should they, or someone they know, be 
dealing with a mental health or substance use problem. 
Measures
Substance use
RPOM was assessed by one item identifying a temporal 
trend pertaining to misuse behavior. The item asked 
“How frequently have you used prescription opioid 
medications (i.e., opioids like Vicodin, OxyContin, 
Tylenol 3, Percocet, Darvocet, buprenorphine, morphine, 
hydrocodone, oxycodone, methadone, fentanyl, or other 
such opioids) for recreational purposes in the past six 
months?” Participants responded using 7-point scale (1-
7) ranging from “1” never, “2” once, “3” more than once, 
“4” every few months, “5” every month, “6” every week 
to “7” most days. Use of other common substances (i.e. 
alcohol, marijuana, methamphetamine, heroin, ecstasy, 
and non-opioid prescription drugs) over the past six 
months were also assessed. Each substance was evaluated 
on the previously mentioned 1-7 scale, responses ranging 
from “1” never to “7” most days. 
Depressive symptomatology 
The Patient Health Questionnaire (PHQ-9) was used 
to assess depressive symptomatology. The PHQ-9 is a 
screening and diagnostic instrument for MDD, widely 
utilized in both clinical and research settings.27,28 The 
PHQ-9 consists of 9 items each addressing specific 
symptoms of depression. The patient indicates whether 
they have been subject to any of the stated symptoms of 
depression over a period of the past two weeks. Sample 
items include “little interest or pleasure in doing things”, 
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“feeling bad about yourself, that you are a failure, or have 
let yourself or your family down”, and “thoughts that you 
would be better off dead or hurting yourself in some way”. 
The participant assigns a score of 0 to 3 indicating how 
often they have been bothered with the symptom, with “0” 
being not at all to “3” nearly every day. Possible scoring 
ranges from 0 to 27. The cut point of  ≥10 was chosen 
to indicate a positive screen for MDD as this threshold 
has demonstrated validity against clinical diagnosis of 
MDD by mental health practitioner.16,27 As scores increase 
from 10 to 27, MDD moves from mild to severe. It is 
important to note, we are not diagnosing individuals, only 
identifying positive and negative screens. In the current 
study, Cronbach’s alpha for the PHQ-9 subscale was 0.85.
Opioid use disorder
OUD is identified by evidence of impaired control, 
social dysfunction, risky use, as well as physiological 
and affective problems associated with the use of opioid 
drugs. The 11 diagnostic criteria for OUD outlined by the 
Diagnostic and Statistical Manual for Mental Disorders, 
5th edition (DSM-V) were directly used to create an 11 
item subscale. Participants responded “yes” or “no” to each 
criterion’s presence over the recall period. For example, 
“Important social, occupational or recreational activities 
are given up or reduced because of my opioid use” and 
“I have a persistent desire or unsuccessful efforts to cut 
down or control my opioid use”. According to the DSM-V, 
manifestation of 2 or more of the criteria indicates the 
possible presence of OUD. As we were not diagnosing 
individuals, answering yes to 2 or more items was treated 
as a positive screen for OUD of at least a mild state. In the 
current study, Cronbach’s alpha for this subscale was 0.80.
Data analysis
Descriptive statistics were computed and presented for 
study variables. Further, statistically significant gender-
based differences in positive screens for disordered use 
and depression, as well as, co-occurring substance use were 
investigated. RPOM, alcohol, marijuana, and non-opioid 
prescription drug misuse were evaluated by frequency. 
Due to restricted variance across frequency scales, cocaine 
and ecstasy were evaluated on the basis of any use during 
the recall period. Similarly, few reports of heroin and 
methamphetamine use were observed, as such, gender 
differences were not tested herein. Differences among 
ordinal variables were evaluated using Mann-Whitney 
U-test, with differences in binary variables calculated 
using Pearson’s chi-square test of independence. Alpha 
levels for significance tests were set at 0.05 and all analytic 
procedures were carried out using IBM SPSS Statistics, 




Participants of the current study were university students 
(n = 104), of both undergraduate and graduate status, who 
self-reported RPOM within the last six months. As seen in 
Table 1, the mean age of participants was 22.1 years (SD 
= 5.9). This sample exhibited a fairly even distribution by 
gender with 57 males and 47 females. Because of limited 
representation by particular ethnic groups, race/ethnicity 
was collapsed to represent whites and members of a 
minority group. The participants identified themselves as 
predominantly white at 87 (83.7%), while 17 participants 
identified as a racial minority. The largest segment of 
students per academic classification were juniors at the 
university (28.8%). Further, less than half of participants 
reported a grade point average less than 3.0. 
Depression
Approximately, 56% of our sample met or exceeded the 
initial cut point for MDD (i.e. ≥10), as designated by 
the PHQ-9 diagnostic instrument (Table 2). Though not 
shown in tabular form, a score ≥15 was observed for 26.9% 
of participants indicating moderate to severe MDD. As 
seen in Table 2, the prevalence of MDD was significantly 
higher among females compared to males at 68.1% and 
45.6%, respectively (P = 0.022). 
Substance use behaviors
As inclusionary criteria, all participants reported RPOM 
at least once in the past six months. As seen in Table 2, 
no significant difference was observed between males 
and females in regard to RPOM frequency (P = 0.793). 
Table 1. Descriptive statistics and major depressive disorder (N=104)
Variables MDDa
Age, mean (SD) 22.1 (5.9)
Gender, No. (%)
Female 47 (45.2) 32 (68.1)
Male 57 (54.8) 26 (45.6)
Race/ethnicity, No. (%)
White/Caucasian 87 (83.7) 46 (52.9)
Others 17 (16.3) 12 (70.6)
Greek affiliation, No. (%)
Fraternity/Sorority 40 (38.5) 25 (62.5)
Non-Greek 64 (61.5) 33 (51.6)
University status, No. (%)
Freshman 23 (22.1) 14 (60.9)
Sophomore 17 (16.3) 7 (41.1)
Junior 30 (28.8) 17 (56.7)
Senior 18 (17.3) 11 (61.1)
Graduate student 16 (15.4) 9 (56.3)
GPAb, No. (%)
<2.0 2 (1.9) 2 (100)
2.0–2.4 9 (8.7) 5 (55.6)
2.5–2.9 23 (22.1) 16 (69.6)
3.0–3.4 36 (34.6) 19 (52.8)
3.5–4.0 34 (32.7) 16 (47.1)
a  MDD represents a score equal to or surpassing the PHQ-9 cut point of 10 
which indicates positive screen for major depressive disorder.
b GPA represents grade point average.
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Among our sample, use of alcohol, marijuana, and non-
opioid prescription drugs were common, at 89.4%, 
73.1%, and 52.9%, respectively, Table 2. Fewer individuals 
reported use of the drugs cocaine (38.5%), ecstasy 
(21.2%), and methamphetamine (7.7%). Encouragingly, 
only one individual reported past six months use of 
heroin. Though no gender difference was identified for 
frequency of RPOM or use of non-opioid prescription 
drugs, significant differences were observed for other 
associated drug use behaviors, Table 2. Specifically, males 
reported more frequent alcohol (P = 0.012) and marijuana 
(P = 0.001) use and were more likely to report cocaine 
use (P = 0.040) than their female counterparts. As noted, 
methamphetamine and heroin use were not evaluated 
on the basis of significant gender differences. However, 
it is worthy of note that only one female reported 
methamphetamine use and no female reported heroin use 
during the study period.
Opioid use disorder 
Seventeen participants (16.3%) screened positive for OUD 
of at least mild severity, Table 2. Our analysis identified 
an association between gender and screening positive for 
OUD (P = 0.016). Specifically, the odds of a positive OUD 
screen were nearly 5 times higher for males when compared 
to female misusers. Of interest, the gender difference in 
OUD exists in absence of a statistical difference in RPOM 
frequency between males and females. 
Discussion
This study identifies staggering mental health problems 
among a specific high-risk population, college students 
who engage in RPOM. The high levels of depression were 
identified by a screening instrument exhibiting robust 
validity against clinical diagnosis.16 Specifically, 55.8% of 
the over-all sample screened positive for MDD of at least 
mild severity. Positive MDD screens were more common 
among female participants. Additionally, 16.3% of 
participants in the current study met classification criteria 
for OUD of at least mild severity, the majority of which 
were males. Collectively, these findings indicate mental 
health complications as an important correlate of RPOM 
among college students.  
A main strength of the current study was its use of 
validated instrumentation for the assessment of depression. 
Few studies have produced correlations between opioid 
misuse and depressive symptomology,6,11,18,21,29 however, 
to our knowledge no studies have attempted to identify 
a prevalence of depression among college students 
who misuse opioids through an established screening 
instrument. Specifically, coping with depression, the 
treatment of emotional pain, and treatment of psychiatric 
distress have been identified as motives for opioid misuse 
among college students.6,11,29 Additionally, prescription 
opioid misuse has been associated with increased odds of 
experiencing depressive symptoms such as hopelessness, 
sadness, and suicidality among this population.18,21 It is 
important, not only for validity, but also for comparative 
purposes that studies attempt to utilize validated 
instrumentation when measuring depression among their 
samples. 
In the current study, estimates of MDD greatly exceeded 
estimates among college students previously reported by 
studies utilizing the same instrumentation.12,22,30 Among 
a sample of general college students, positive MDD 
screens for 5.2% and 4.1% of undergraduate and graduate 
students, respectively, were reported.22 Another study 
of over 14 000 students from 26 universities across the 
United States produced positive MDD screens for 9% of 
participants.12 Additionally, a study of medical students 
reported 14.3% scoring 10 or above on the PHQ-9.30 For 
perspective, a recent study reported that among chronic 
non-cancer pain patients (n = 785) undergoing chronic 
opioid therapy, 14.6% screened positive for MDD utilizing 
the PHQ-9 and cut points applied by the current study.28 
Consistent with our findings, literature shows females 




Female (n=47) Male (n=57) χ2 OR (95% CI)
% reporting % reporting
MDDa 55.8 68.1 45.6 5.27* 0.39 (0.18–0.88)
OUDb 16.3 6.4 24.6 6.23c,* 4.78 (1.28–17.80)
Cocaine 38.5 27.7 47.4 4.23* 2.35 (1.03–5.37)
Ecstasy 21.2 12.8 28.1 3.62 2.67 (0.95–7.49)
Total
% reporting
Median Median U Effect Size
Prescription opioid misuse frequency 100 3.0 3.0 1301.50 0.001
 Alcohol use frequency 89.4 5.0 6.0 972.00* 0.062
Marijuana use frequency 73.1 3.0 5.0 830.00** 0.112
Non-opioid prescription drugs misuse frequency 52.9 1.0 3.0 1148.50 0.017
Abbreviations: OR, odds ratio; CI confidence interval. 
Note. Effect size measured as Eta2.
a Positive screen for major depressive disorder (MDD) classified by a PHQ-9, not physician diagnosis. 
b Positive screen for opioid use disorder (OUD). 
c Fisher exact test. 
* P < 0.05; ** P < 0.01.
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as more prone to MDD.12,17,22,23,30 A systematic review 
of depressive prevalence among university students 
identified only one study where males exhibited greater 
risk.17 Prospective study among adolescents suggests that 
young females are more reactive to stress and thus more 
prone to development of depression.31 As college is a high 
stress environment and the fact that evidence suggests a 
bidirectional relationship between depression and opioid 
use,32 this may partially explain our findings. 
To the best of our knowledge this was also the first 
study to examine the presence of OUD explicitly among 
a college sample. We recommend that future study 
incorporate measures of disordered use when studying 
this behavior to better understand the deleterious effects 
these drugs impose on student’s psychosocial functioning. 
OUD is a common correlate of long-term drug therapy.25 
Our OUD findings, at 16%, are concerning as these are 
not daily medical users. Previous study indicates that as 
many as half of individuals with OUD have co-occurring 
MDD.33 Similarly, in our sample, just more than half of 
those screening positive for OUD also exhibited positive 
screens for MDD. In the current study, significantly more 
students screening positive for OUD were male which 
may reflect DSM-V reports that males with mental health 
disorders are more likely to have a co-occurring substance 
use disorder. 
RPOM frequency was generally low among the entire 
sample, however, attempting to quantify frequency was of 
interest being that studies among this population typically 
treat opioid use as a dichotomy.5,6,11,34 Interestingly, we 
observed no significant difference in RPOM frequency 
between males and females, however, significant 
differences were identified for alcohol, marijuana, and 
cocaine use. As opioid effects are intensified when used 
in combination with other substances,35 this finding 
may not only indicate males at increased risk for RPOM 
outcomes such as overdose, but may have caused males to 
better associate RPOM with the physical, psychological, 
and social impairments addressed by the OUD screening 
items. 
Taken collectively, gender differences in MDD, OUD, 
co-occurring substance use, and a lack of difference 
in frequency of RPOM may highlight incompatible 
determinant factors for recreational misuse. Though 
speculative, our operational definition of “recreational 
misuse” may have created differential associations in the 
minds of participants. For example, “to relax” may have 
been perceived as a means of maladaptive coping to escape 
negative psychological states among females (e.g. self-
medication of stress or sadness), whereas males may have 
related “recreational misuse” to other elements presented 
in the operational definition (i.e. have fun, experience 
euphoric effects, etc). Furthermore, we did not assess the 
dosage of opioids consumed which may have partially 
explained our findings pertaining to OUD. Reliability of 
this information would be problematic when quantifying 
morphine equivalents among recreational users. Indeed, 
if euphoric effects are the goal of RPOM, one may be 
inclined to consume higher dosage.  
There were several limitations to address in the current 
study. This study included a rather small sample of college 
students (n = 104) from a single university which may 
impact the generalizability of findings. However, the 
randomized recruitment strategy utilized may aid in 
countering this limitation. It is important to indicate, as 
outlined in the methodology, the 104 students reporting 
past-6 month RPOM constitutes approximately 10% of 
participants successfully recruited through a randomized 
process. Studies among college students assessing 
prescription opioid misuse over recall periods of one 
year or less typically produce estimates of misuse at less 
than 10%.5,6 Thus, deriving a larger sample would have 
been difficult among this population. Further, the self-
report nature of this study may have resulted in recall bias, 
particularly with regard retrospective frequency. Another 
limitation regarding frequency was the fact that the scale 
adapted from36 included once choice identified as “more 
than once”. Though instructed to read each response 
carefully prior to choosing an option, participants may 
have seen this choice and selected it without considering 
the further alternatives. Should this, indeed, be the case 
RPOM may have occurred more frequently than reported 
among this sample of students. Moreover, we cannot 
provide causal linkage between variables as this study was 
cross-sectional in nature. 
Conclusion
Findings suggest that gender differences exist in both 
depression levels and co-occurring substance use among 
college students who engage in RPOM. In general, 
females were more likely than their counterparts to 
exhibit a positive screen for MDD. While no differences 
were identified in RPOM frequency between groups, 
males tended to engage in more non-opioid substance 
use. Regardless of significant gender differences, positive 
screens for MDD as well as substance use behavior were 
high among males and females highlighting a need for 
specialized intervention efforts among this high-risk 
subpopulation of students. Future study should attempt 
to procure larger samples and longitudinal cohort designs 
capable of probing temporal relationships between RPOM 
and mental health dysregulation throughout college 
progression.  
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